Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
DECODING IMMUNE DYSREGULATION: TOLERANCE LOSS AND THE ROLE OF GENDER, ETHNICITY, AND DIVERSITY IN SKIN HEALTH
Description
The discussion focuses on immune dysregulation related to disorders such as autoimmunity, examining the influence of gender, ethnicity, and diversity on skin health. It opens with a look at how autoimmune diseases do not affect all populations equally, particularly highlighting cases like monogenetic diseases that reveal flaws in immune function. The talk emphasizes a significant female predominance in autoimmune disorders, with biological factors such as hormonal differences being noted, though with complexity and varying impacts across specific diseases. Racial disparities in conditions like lupus are also explored, showcasing how underlying genetic variations relate to disease prevalence and severity, particularly among Black women, who present with more aggressive forms of lupus. Important aspects include the roles of specific genes, immune responses, and T regulatory cell therapies in addressing these diseases. The overarching theme is the multifactorial nature of autoimmunity, where genetic, environmental, and social factors interplay to influence health outcomes, warranting more inclusive research and therapeutic approaches.
View moreConclusions
- Autoimmune diseases affect approximately 5-10% of the population.
- Monogenetic diseases provide insights into autoantibody production and immune responses.
- Autoimmune diseases are three times more common in women than men.
- Sex differences in autoimmunity are multifactorial, influenced by genetic, chromosomal, environmental, and hormonal factors.
- Major genetic factors in sex differences include XIST and VGLL3.
- Lupus is two times more common and more severe in black individuals compared to other racial groups.
- Stronger Toll-like receptor (TLR) and interferon alpha (IFNa) signaling is observed in black patients with lupus.
- CAR-T regulatory cell therapies represent a flexible approach to target multi-organ inflammation in autoimmune diseases.
- Eisenbarth et al 2004
- Meyer et al 2016
- Billi et al 2019
- Fairweather et al 2024
- Slight-Webb et al 2023